Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38


Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.

Baum SJ, Wade RL, Xiang P, Arellano J, Cerezo Olmos C, Nunna S, Chen CC, Carter CM, Desai NR.

Ther Clin Risk Manag. 2019 Nov 13;15:1325-1332. doi: 10.2147/TCRM.S216606. eCollection 2019.


Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators.

N Engl J Med. 2020 Jan 16;382(3):244-255. doi: 10.1056/NEJMoa1905239. Epub 2020 Jan 1.


Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.

Baum SJ, Sampietro T, Datta D, Moriarty PM, Knusel B, Schneider J, Somaratne R, Kurtz C, Hohenstein B.

J Clin Lipidol. 2019 Nov - Dec;13(6):901-909.e3. doi: 10.1016/j.jacl.2019.10.003. Epub 2019 Oct 11.


Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.

Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB.

JAMA. 2019 Nov 12;322(18):1780-1788. doi: 10.1001/jama.2019.16585. Erratum in: JAMA. 2020 Jan 21;323(3):282.


Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives.

Shapiro MD, Maron DJ, Morris PB, Kosiborod M, Sandesara PB, Virani SS, Khera A, Ballantyne CM, Baum SJ, Sperling LS, Bhatt DL, Fazio S.

J Am Coll Cardiol. 2019 Oct 15;74(15):1926-1942. doi: 10.1016/j.jacc.2019.08.1016. Review.


Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.

Myers KD, Farboodi N, Mwamburi M, Howard W, Staszak D, Gidding S, Baum SJ, Wilemon K, Rader DJ.

Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005404. doi: 10.1161/CIRCOUTCOMES.118.005404. Epub 2019 Jul 23.


Access to PCSK9 Inhibitors.

Baum SJ, Lepor NE, Robinson JG.

Rev Cardiovasc Med. 2018;19(S1):S47-S50. No abstract available.


Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag.

Baum SJ, Brown AS.

Rev Cardiovasc Med. 2018;19(S1):S25-S30. Review.


Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, Baum SJ, Bourbon M, Carrié A, Cuchel M, de Ferranti SD, Defesche JC, Freiberger T, Hershberger RE, Hovingh GK, Karayan L, Kastelein JJP, Kindt I, Lane SR, Leigh SE, Linton MF, Mata P, Neal WA, Nordestgaard BG, Santos RD, Harada-Shiba M, Sijbrands EJ, Stitziel NO, Yamashita S, Wilemon KA, Ledbetter DH, Rader DJ; Convened by the Familial Hypercholesterolemia Foundation.

J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. doi: 10.1016/j.jacc.2018.05.044. Review.


The American Society for Preventive Cardiology.

Baum SJ.

Clin Cardiol. 2018 Jun;41(6):709. doi: 10.1002/clc.22982. Epub 2018 Jun 8. Review. No abstract available.


The 2017 high blood pressure clinical practice guideline: The old and the new.

Schwartzbard AZ, Newman JD, Weintraub HS, Baum SJ.

Clin Cardiol. 2018 Mar;41(3):279-281. doi: 10.1002/clc.22905. Epub 2018 Mar 25. No abstract available.


PCSK9 inhibitor valuation: A science-based review of the two recent models.

Baum SJ, Cannon CP.

Clin Cardiol. 2018 Apr;41(4):544-550. doi: 10.1002/clc.22924. Epub 2018 Mar 7. Review.


Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).

McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH.

Am J Cardiol. 2018 Apr 15;121(8):940-948. doi: 10.1016/j.amjcard.2017.12.040. Epub 2018 Feb 2.


Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.

Amrock SM, Duell PB, Knickelbine T, Martin SS, O'Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ, Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, Moriarty PM, Knowles JW, Ahmad ZS.

Atherosclerosis. 2017 Dec;267:19-26. doi: 10.1016/j.atherosclerosis.2017.10.006. Epub 2017 Oct 6.


The 2017 American Society for Preventive Cardiology Congress and Experts Course.

Baum SJ.

Clin Cardiol. 2017 Aug;40(8):520. doi: 10.1002/clc.22765. Epub 2017 Jul 24. No abstract available.


Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease.

Knowles JW, Howard WB, Karayan L, Baum SJ, Wilemon KA, Ballantyne CM, Myers KD.

Circulation. 2017 May 30;135(22):2204-2206. doi: 10.1161/CIRCULATIONAHA.117.027705. Epub 2017 Apr 26. No abstract available.


PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.

Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K.

Clin Cardiol. 2017 Apr;40(4):243-254. doi: 10.1002/clc.22713. Epub 2017 Mar 22. Review.


A review of the evidence for alternative and complementary medical approaches in the prevention of atherosclerotic cardiovascular disease and diabetes.

Nieves JP, Baum SJ.

Cardiovasc Endocrinol. 2017 Feb 15;6(1):39-43. doi: 10.1097/XCE.0000000000000118. eCollection 2017 Mar. Review.


The American Society for Preventive Cardiology: Our 30-year legacy.

Wong ND, Sperling LS, Baum SJ.

Clin Cardiol. 2016 Nov;39(11):627-630. doi: 10.1002/clc.22590. Epub 2016 Oct 26. No abstract available.

Supplemental Content

Loading ...
Support Center